<h4>Objective</h4>To analyze and evaluate the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease, and to provide evidence-based basis for clinical rational treatment.<h4>Methods</h4>Relevant literatures on the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease published in domestic and foreign databases were retrieved and collected. The gene discussed is SLC5A2; the disease is diabetes mellitus.